Sex: M
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: Migraine; Stiffness; Neck swelling; Increased blood pressure; Lower extremities weakness of; Pain; Itchy rash; Painful joints; Vaccination site pain; Lethargic; This spontaneous case was reported by a consumer and describes the occurrence of LETHARGY (Lethargic), MIGRAINE (Migraine), MUSCULOSKELETAL STIFFNESS (Stiffness), SWELLING (Neck swelling) and BLOOD PRESSURE INCREASED (Increased blood pressure) in a 49-year-old male patient who received mRNA-1273  for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Psoriatic arthritis.    Concomitant products included METHOTREXATE for an unknown indication.   On an unknown date, the patient received first dose of mRNA-1273  (Intramuscular) 1 dosage form On an unknown date, received second dose of mRNA-1273 ( (Intramuscular) dosage was changed to 1 dosage form and ADALIMUMAB (HUMIRA) (Subcutaneous) 1 dosage form., ADALIMUMAB (HUMIRA) (Subcutaneous) dosage was changed to 1 dosage form and ADALIMUMAB (HUMIRA) (Subcutaneous) dosage was changed to 1 dosage form. On 08-Mar-2022, the patient experienced LETHARGY (Lethargic). On an unknown date, the patient experienced MIGRAINE (Migraine), MUSCULOSKELETAL STIFFNESS (Stiffness), SWELLING (Neck swelling), BLOOD PRESSURE INCREASED (Increased blood pressure), MUSCULAR WEAKNESS (Lower extremities weakness of), PAIN (Pain), RASH PRURITIC (Itchy rash), ARTHRALGIA (Painful joints) and VACCINATION SITE PAIN (Vaccination site pain). At the time of the report, LETHARGY (Lethargic), MUSCULAR WEAKNESS (Lower extremities weakness of), PAIN (Pain) and ARTHRALGIA (Painful joints) had not resolved, MIGRAINE (Migraine) and VACCINATION SITE PAIN (Vaccination site pain) had resolved, MUSCULOSKELETAL STIFFNESS (Stiffness) outcome was unknown and SWELLING (Neck swelling), BLOOD PRESSURE INCREASED (Increased blood pressure) and RASH PRURITIC (Itchy rash) was resolving.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Blood pressure measurement: Unknown date BLOOD PRESSURE: Increased.     The action taken with mRNA-1273  (Intramuscular) was unknown.       There was no reported medical history .  On unknown dates, the patient experienced sore arm after first two covid vaccine shot, migraine after first two covid vaccine shot, stiffness, rashes on neck that also had swelling during time of change of weather/ had a itching rash on neck, pain in ankles, knees, shoulders in cold weather, experiences increase blood pressure with physical exertion, weakness in ankles and toes and occasional pain. on 08-Mar-2022, the patient experienced felt lethargic when the weather changed. On unknown dates, sore arm after first two covid vaccine shot and migraine after first two covid vaccine shot resolved. moderna covid-19 vaccine (elasomeran) was also considered suspect .  It was unknown if patient was enrolled in a COVID-19 Vaccine Trial .  The patient was treated with TYLENOL .  The reporter's causality for the event (s) of felt lethargic when the weather chanced, sore arm after first two covid vaccine shot, migraine after first two covid vaccine shot, experiences increase blood pressure with physical exertion and occasional pain was not provided. the reporter's causality for the event (s) of stiffness, rashes on neck that also had swelling during time of change of weather/ had a itching rash on neck unknown onset and pain in ankles, knees, shoulders in cold weather with Humira (adalimumab) was a reasonable possibility. the reporter i s causality for the event (s) of rashes on neck that also had swelling during time of change of weather/had a itching rash on neck unknown onset and weakness in ankles and toes with Humira (adalimumab) was no reasonable possibility .  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in   Most recent FOLLOW-UP information incorporated above includes:  Significant follow up appended on 11-Apr-2022 included Event 'Pain' , suspect drug description and updated narrative.